

## **Cancer Partners first in Lincoln to offer new treatment for prostate cancer**

(LINCOLN, NEB.) SEPTEMBER 2, 2022 - Two local cancer patients are the first in the area to receive a new treatment for prostate cancer. Cancer Partners of Nebraska (Cancer Partners) is the first in Lincoln to offer PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan) which is a drug that targets PSMA -- a protein found on the surface of most prostate cancer cells.

Prostate cancer is the second leading cause of cancer death for men in the United States, according to the American Cancer Society. Joseph Kam Chiu, MD, Cancer Partners Radiation Oncologist said, "This new treatment is another state-of-the-art tool we can use to treat prostate cancer to achieve better patient outcomes."

Treatments such as chemotherapy cannot identify PSMA specifically and may come with some side effects. PLUVICTO™ seeks out and delivers a high dose of radiation directly to the areas of disease throughout the body but bypasses healthy cells. This can mean fewer side effects like nausea, vomiting and hair loss. The drug is typically given intravenously every six weeks for up to six treatments.

"We are excited to provide our patients with this major clinical advancement treatment option," said Matthew Bideaux, Radiology Director of Cancer Partners. "Prostate cancer can be challenging to treat. We anticipate that this treatment to be another step toward increasing survival rates."

Cancer Partners of Nebraska provides comprehensive cancer care in Lincoln and eleven greater Nebraska communities. Cancer Partners combines advanced medical oncology, radiation oncology, surgical oncology and multiple oncology support services at their two Lincoln locations. For more information, visit [CancerPartners.com](https://CancerPartners.com).